HCWB news

HCW Biologics Inc. signed a Notes Purchase Agreement dated October 2026 with Streeterville Capital, LLC, to sell promissory notes for a total purchase price of $10 million.

HCW Biologics and Akron Biotech entered an exclusive distribution agreement for the commercialization of HCW11-006 as a reagent to produce highly functional human CAR-T cells, supported by pre-payment commitments.

Documents a form for pre-funded warrants indicating shares for purchase and an initial exercise date of 2026; these instruments typically support capital raising efforts.

The company regained compliance with Nasdaq's bid price rule after completing a mandatory one-for-six reverse stock split. This reinstatement is subject to a monitoring period through June 17, 2027.

HCW Biologics announced positive preliminary results from its Phase 1 clinical trial of HCW9302, with all three patients in the second dose cohort showing ≥25% improvement in alopecia severity scores and no dose-limiting toxicities reported. The well-tolerated results support the company's goal to e…

HCW Biologics exercised its option to regain exclusive ex vivo rights to HCW9206 and HCW9201 compounds from Wugen at no cost while retaining upfront fees including 2.2M Wugen shares. The move positions the company to commercialize CAR-T manufacturing reagents that published data suggests may reduce …